#easd25
LightNews LightNews
danieljdrucker.bsky.social
Are some GLP-1 medicines more cardioprotective than others? #easd25 A new real world study using US Medicare data www.novonordisk.com/content/nnco...
September 18, 2025 at 10:26 AM
danieljdrucker.bsky.social
Among many highlights today #easd25 @easdnews.bsky.social
The Novo Nordisk Foundation
Prize lecture novonordiskfonden.dk/en/news/scie...
Scientist who uncovered how hidden fat drives diabetes wins major research prize - Novo Nordisk Fonden
novonordiskfonden.dk
September 18, 2025 at 8:26 AM
danieljdrucker.bsky.social
#EASD25 highlights. Modern GLP-1 medicines such as tirzepatide are cardioprotective, can/should be tested using ethical trial designs and the dose response for metabolic endpoints does not perfectly mirror that for reduction of MACE #CVD #T2D
September 18, 2025 at 7:30 PM
endpts.com
At #EASD25, Regeneron shared new data showing its anti-myostatin antibody may help preserve muscle in patients taking Wegovy for obesity.
Regeneron posts update on its muscle-sparing approach, a new quadruple agonist emerges at #EASD25
Updates from Regeneron, Biomed Industries, Sun Pharma, QL Biopharma, and Novo Nordisk were presented at EASD.
endpoints.news
September 19, 2025 at 7:05 PM
medscapefrancais.bsky.social
Diabète MODY : quelle prévalence et quelle expression en population générale ? #EASD25
ms.spr.ly/63325t8Nch
Diabète MODY : quelle prévalence et quelle expression en population générale ?
Dans la population générale, l’expression du diabète de type MODY est-elle plus hétérogène et plus fréquente ? Et que donnerait la prescription d’empagliflozine dans le MODY lié à HNF1A ? Éléments de réponse avec deux études détaillées.
ms.spr.ly
October 29, 2025 at 10:52 AM
medscapefrancais.bsky.social
Sémaglutide oral : premier agoniste du récepteur du GLP-1 cardioprotecteur par voie orale ? #EASD25
ms.spr.ly/63327t834T
Sémaglutide oral : premier agoniste du récepteur du GLP-1 cardioprotecteur par voie orale ?
La forme orale du sémaglutide réduit les événements cardiovasculaires majeurs chez les patients DT2 à haut risque, selon l’essai SOUL. Mais des incertitudes subsistent sur son impact sur la fonction rénale et l’intérêt de l’associer aux inhibiteurs du SGLT2.
ms.spr.ly
October 28, 2025 at 11:11 AM
longtail-news.bsky.social
Feed: "Endpoints News"
By: Elizabeth Cairns on Thursday, September 18, 2025
#EASD25: Lilly seeks Mounjaro approval for children with diabetes following Phase 3 hit
Eli Lilly seeks approval for diabetes drug Mounjaro in children after Phase 3 trial shows blood sugar and weight reduction compared to placebo.
endpoints.news
September 19, 2025 at 1:35 AM
longtail-news.bsky.social
Feed: "Endpoints News"
By: Elizabeth Cairns on Tuesday, September 16, 2025
#EASD25: Lilly unwraps more Phase 3 obesity pill data, but they still lag behind Novo's oral Wegovy
Additional data from a Phase 3 trial studying Eli Lilly's GLP-1 pill orforglipron continue to underline its lackluster performance in nondiabetic obesity patients when lined up against the oral form of Novo Nordisk’s Wegovy.
endpoints.news
September 18, 2025 at 1:21 AM
springermedicine.com
Catch up on the latest breakthroughs in #diabetes research from #EASD25 with our congress hub.

Access for free 👉 buff.ly/wmxk9xF

#MedNews #MedSky
September 22, 2025 at 2:15 PM
biotechnetworks.bsky.social
MWBN Trending: #EASD25: Lilly unwraps more Phase 3 obesity pill data, but they still lag behind Novo’s oral Wegovy https://zpr.io/SBGv9PC5NcGa
September 17, 2025 at 8:43 PM
firstwordgroup.com
EASD25: Studies demonstrate machine learning's predictive prowess in diabetes #EASD2025 firstwordhealthtech.com/story/6093437
September 18, 2025 at 12:35 PM